Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $186.09 and traded as high as $195.83. UCB shares last traded at $192.00, with a volume of 251 shares changing hands.
UCB Trading Down 1.5 %
The stock has a 50 day moving average of $186.09 and a two-hundred day moving average of $173.83. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Articles
- Five stocks we like better than UCB
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Stock Market Upgrades: What Are They?
- How Do Stock Buybacks Affect Shareholders?
- 3 REITs to Buy and Hold for the Long Term
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
